

OVCAR-3 | 300307

Description	OVCAR-3	,	,	60	.	Ovcar 3	,
	OVCAR-3				.		
	OVCAR-3				.		,
	, OVCAR3		,	,		.	

Organism

Tissue

Disease

Metastatic site

Synonyms OVCAR-3, Ovcar-3, OVCAR.3, NIH:Ovcar-3, NIH:OVCAR3, NIH-OVCAR-3, NIHOVCAR3, OVCAR3, Ovcar3, Ovcar3

Age 60

Gender

Ethnicity

Growth properties

Citation OVCAR3(300307)

Biosafety level 1

NCBI_TaxID 9606

CellosaurusAccession CVCL_0465

OVCAR-3 | 300307

Receptors expressed , ,

Isoenzymes G6PD, B, PGM1, 1, PGM3, 1, ES-D, 1, AK-1, 1, GLO-1, 1

Tumorigenic ,

Ploidy status

MSI-status (MSS)

Culture Medium RPMI 1640, w: 2.0mM , w: 2.0g/L NaHCO3(820700a)

Supplements 20% FBS 0.01 mg/mL .

Dissociation Reagent

Doubling time 40~60

Subculturing PBS . T25 3~5ml, T75 5~10ml PBS . T25

Split ratio 1:4 1:6

Seeding density 2×10^4 /cm²

Fluid renewal 2~3

Freeze medium (FBS) + 10% DMSO , CM-1(Cytion 800100)

OVCAR-3 | 300307

Thawing and Culturing Cells

1. .
2. -150°C , 3 .
3. 37°C 40~60 .
4. , 70% .
5. 8ml 15ml .
6. 300 x g 3 .
7. 10ml . T25 , T25
8. .

Incubation Atmosphere

37°C, 5% CO₂ .

Flask Coating

Freezing Procedure

-78°C .

Shipping Conditions

-78°C .

Storage Conditions

-150°C -196°C .80°C .

/ / HLA

Sterility

PCR .

OVCAR-3 | 300307

STR

- CSF1PO:** 11, 12
- D13S317:** 12
- D16S539:** 12
- D5S818:** 11, 12
- D7S820:** 10
- TH01:** 9.9.3
- TPOX:** 8
- vWA:** 17
- D3S1358:** 17, 18
- D21S11:** 29, 31.2
- D18S51:** 13
- Penta E:** 7,13
- Penta D:** 12, 13
- D8S1179:** 10,15
- FGA:** 21

HLA

- A*:** 02:01:01, '29:02:01
- B*:** '07:02:01, '58:01:01
- C*:** '07:02:01, '07:18:01
- DRB1*:** '08:01:01, '08:04:01
- DQA1*:** '04:01:01, '04:01:02
- DQB1*:** '04:02:01
- DPB1*:** '02:01:02, '04:01:01
- E:** '01:01:01